
SELLAS Life Sciences rose 429.8% from $1.41 to $7.47, ahead of the S&P 500's +11.2%. Its worst day was Jan 6 (−18.0%), and its low came Nov 17 at $1.41.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
SELLAS Life Sciences shares rose 18.8%, while the S&P 500 rose 0.2%.
+18.8% · S&P 500 +0.2%
EPS of $-0.05 beat the $-0.06 estimate on $0.00 revenue.
−8.5% · S&P 500 −1.4%
Story events cover the past 12 months · Times ET
EPS of $-0.05 beat the $-0.06 estimate on $0.00 revenue.
+25.1%, the year's best day · S&P 500 +0.6%
SELLAS Life Sciences shares rose 24.7%, while the S&P 500 rose 1.6%.
+24.7%, on 33M shares, the year's heaviest volume · S&P 500 +1.6%
EPS of $-0.05 missed the $-0.04 estimate on $0.00 revenue.
+6.5% · S&P 500 +0.3%
SELLAS Life Sciences closed at its highest level of the year, 996.5% above where the year started.
+15.4% · S&P 500 +0.4%
EPS of $-0.05 beat the $-0.05 estimate on $0.00 revenue.
−2.1% · S&P 500 −0.4%
Where it ended: a close of $7.47 on Nov 16, 2026.
Nothing in the past 12 months.
All SLS dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for SLS and SPY from Benzinga historical bars. Not investment advice.